Carbamazepine

Formulation

The table below describes the formulation of carbamazepine and the controls morphine sulfate and gabapentin for the following in vivo experiments.

Experiment(s) Compound Dose(s) mg/kg Correction factor Dose volume mL/kg Route Vehicle Suspension / Solution
Pharmacokinetics Carbamazepine 10, 100 1.00 4 PO 0.5% MC Suspension
Irwin, Rotarod Carbamazepine 10, 30, 100, 300 1.00 4 PO 0.5% MC Suspension
Plantar incision, Carbamazepine 3, 10, 30, 100 1.00 4 PO 0.5% MC Suspension
L5/L6 SNL
Plantar incision Morphine 6 1.33 1 SC Saline Solution
L5/L6 SNL Gabapentin 60 1.00 1 PO Saline Solution

L5/L6 SNL = L5/L6 spinal nerve ligation; PO = per os; SC = subcutaneous; 0.5% MC = 0.5% methylcellulose in water


Results

Expand and Collapse accordion content

Method: Protein Binding
A table shows the results of rapid equilibrium dialysis to assess protein binding and percent recovery of carbamazepine. In rat plasma, carbamazepine was 65.5% bound to protein and 34.5% unbound and had a recovery of 108.3%. In rat brain homogenate, carbamazepine was 25% bound to protein and 75% unbound and had a recovery of 98.9%. Analysis of carbamazepine returned values consistent with literature values.

Method: Rat Rotarod Animals were balanced across treatment groups based on body weight. Animals that achieved a latency of 40 seconds during the baseline trial were included in the study. Experimenters assessing behavior were masked to treatment. Group size was determined using power analysis.
Two graphs show the latency for male or female rats to fall off a rotarod apparatus. Responses are shown at the following time points: baseline (before treatment) and at 0.5, 1, and 4 hours after treatment with vehicle (0.5% methylcellulose, delivered PO) or carbamazepine (10, 30, 100, or 300 mg/kg, delivered PO). There were 10 rats per group. Neither males nor females had a significant interaction of time x treatment in a two-way repeated measures ANOVA.


This work was conducted by PsychoGenics Inc. (Paramus, NJ) in collaboration with PSPP, NINDS, NIH under contract # 75N95019D00026. Prescribing information for clinically used controls can be found at labels.fda.gov. Information for icons representing experimental design details can be found through the NINDS Office of Research Quality https://go.nih.gov/Yw2tHGI.